Aktienanalyse zu Voyager Therapeutics Inc (VYGR)VYGRVoyager Therapeutics Inc

Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Voyager Therapeutics Inc (VYGR) appears to be a good buy right now, primarily due to its recent positive price momentum and upcoming clinical trials that could enhance its market position. The current price is $3.54, and the stock has shown a 5-day change of +4.42%, indicating upward momentum. Additionally, the RSI is at 77.43, suggesting it is nearing overbought territory but still has room for growth. The forward P/E of 8.44 indicates that the stock may be undervalued relative to its future earnings potential. However, the main risk is the significant net loss reported in Q1 2026 of $27.9 million, which highlights ongoing financial challenges that could affect investor sentiment.

10 analysts cover VYGR: 9 rate it Buy, 1 Hold and 0 Sell. The average price target is 13.20.